
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Rare Autoantibody Diseases
SPRING HOUSE, PA — Johnson & Johnson has recently revealed encouraging results from trials of nipocalimab, a new drug that could offer hope to adults suffering from generalized myasthenia gravis …
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Rare Autoantibody Diseases Read More